Merck KGaA / MilliporeSigma (CDMO) vs Piramal Pharma Solutions: CDMO Comparison

Side-by-side comparison of Merck KGaA / MilliporeSigma (CDMO) and Piramal Pharma Solutions on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Darmstadt, DE · St. Louis, MO
Signal Score
82/100
Quality (FDA + GMP)
99/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
2
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
22
Capacity
Modalities
mRNA, Biologics, Cell Therapy
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score
84/100
Quality (FDA + GMP)
96/100
FDA inspections
5
— NAI / VAI / OAI
1 / 4 / 0
FDA warning letters
0
EMA GMP certificates (active)
1
MHRA GMP certificates (compliant)
12
Clinical programs (matched)
0
Capacity
Modalities
Biologics, ADC

Key differences

  • Piramal Pharma Solutions has more FDA inspections on record (5 vs 2) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Piramal Pharma Solutions maintains 12 MHRA / UK GMP certificates; Merck KGaA / MilliporeSigma (CDMO) does not.
  • Merck KGaA / MilliporeSigma (CDMO) appears as a manufacturing partner on more matched clinical programs (22 vs 0) — a broader sponsor book.

On a 13-modality CDMO landscape, both Merck KGaA / MilliporeSigma (CDMO) and Piramal Pharma Solutions qualify as Biologics manufacturers; Piramal Pharma Solutions carries the higher composite Signal Score for Biologics programs in this comparison.

What to evaluate for Biologics programs

Both Merck KGaA / MilliporeSigma (CDMO) and Piramal Pharma Solutions qualify as Biologics CDMOs. When choosing between them for Biologics programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Scale & bioreactor fit

Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.

Cell line & process development

Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.

Regulatory track record

Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.

Drug substance to drug product

Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.

See all Biologics CDMOs ranked by Signal Score →

Frequently asked: Merck KGaA / MilliporeSigma (CDMO) vs Piramal Pharma Solutions

Which has the stronger FDA inspection record, Merck KGaA / MilliporeSigma (CDMO) or Piramal Pharma Solutions?

Both Merck KGaA / MilliporeSigma (CDMO) and Piramal Pharma Solutions maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Merck KGaA / MilliporeSigma (CDMO) has 2 FDA inspections on record; Piramal Pharma Solutions has 5.

How do Merck KGaA / MilliporeSigma (CDMO) and Piramal Pharma Solutions compare on European GMP coverage?

Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Piramal Pharma Solutions holds 1 active EMA GMP certificate and 12 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Merck KGaA / MilliporeSigma (CDMO) or Piramal Pharma Solutions?

Merck KGaA / MilliporeSigma (CDMO) is matched to 22 ClinicalTrials.gov records as a manufacturing partner; Piramal Pharma Solutions is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for Biologics manufacturing — Merck KGaA / MilliporeSigma (CDMO) or Piramal Pharma Solutions?

Both Merck KGaA / MilliporeSigma (CDMO) and Piramal Pharma Solutions are tagged as Biologics CDMOs in our directory, so both are credible options for Biologics programs. The most important differentiator for Biologics selection is typically scale & bioreactor fit: Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Merck KGaA / MilliporeSigma (CDMO) carries a Signal Score of 82/100 and Piramal Pharma Solutions carries 84/100 — essentially tied for Piramal Pharma Solutions. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Merck KGaA / MilliporeSigma (CDMO) and Piramal Pharma Solutions for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.